CG Oncology, Inc. Common stock (CGON)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 4:33 PM ET
CG Oncology, Inc. Common stock (CGON) Statistics
CG Oncology, Inc. Common stock (CGON) has a market cap of $7.57B and an enterprise value of $7.55B. It kept -3851.09% of revenue as net income over the last 12 months. Revenue grew 169.85% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 0.33% below the market cap, as cash exceeds debt.
| Market Cap | $7.57B |
|---|---|
| Enterprise Value | $7.55B |
| Latest price (Nov 17, 2026) | $78.94 |
Key Dates
The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 7.1x |
|---|---|
| P/TBV Ratio | 7.2x |
Price Statistics
The stock is up 92.49% over 52 weeks and trades 15.49% above its 50-day average.
| Beta (1Y) | 0.94 |
|---|---|
| 52-Week Change | +92.49% |
| 1-Month Change | +31.65% |
| 3-Month Change | -2.16% |
| 6-Month Change | +24.71% |
| Total Return (1Y) | +92.49% |
| Return vs SPY (1Y) | +73.96% |
| Max Drawdown (1Y) | -27.41% |
| Max Drawdown (3Y) | -67.47% |
| Sharpe Ratio (1Y) | 1.08 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $68.35 |
| 200-Day Average | $66.96 |
| 52-Week Range | $37.01 to $93.95 |
| RSI (14 Days) | 61.7 |
| Average Volume (20 Days) | 1.76M |
Financial Position
Current assets cover 21.70x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 21.70x |
|---|---|
| Quick Ratio | 21.68x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -21.06% and return on equity is -23.96% over the last 12 months.
| Return on Equity (ROE) | -23.96% |
|---|---|
| Return on Assets (ROA) | -22.69% |
| Return on Invested Capital (ROIC) | -21.06% |
| ROA (5Y Average) | -20.45% |
| Asset Turnover | 0.01x |
| Inventory Turnover | 11.65x |
| Receivables Turnover | 11.39x |
| Cash Conversion Cycle | -262 days |
Scores
CGON has an Altman Z-Score of 75.07, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 75.07 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $6.17M over the last 12 months.
| Revenue | $6.17M |
|---|---|
| Revenue Growth (YoY) | +169.85% |
| Gross Profit | -$6.46M |
| Operating Income | -$264.74M |
| Pretax Income | -$237.46M |
| Net Income | -$237.46M |
| Reported EPS (TTM) | -$2.76 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.38% of the $1.05B in total assets.
| Cash and Equivalents | $28.25M |
|---|---|
| Total Debt | $3.00M |
| Net Cash | $25.25M |
| Net Cash Per Share | $0.28 |
| Working Capital | $961.30M |
| Shareholder Equity | $990.97M |
| Book Value Per Share | $11.15 |
| Tangible Book Value | $980.14M |
| Tangible Book Per Share | $11.03 |
| Total Assets | $1.05B |
| Total Liabilities | $55.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.89M of capital spending, operating cash flow left -$189.17M of free cash flow.
| Operating Cash Flow | -$187.28M |
|---|---|
| Capital Expenditures | $1.89M |
| Free Cash Flow | -$189.17M |
| FCF Per Share | -$2.13 |
| Depreciation and Amortization | $4.65M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4293.53%.
| Gross Margin | -104.77% |
|---|---|
| Operating Margin | -4293.53% |
| Pretax Margin | -3851.09% |
| Net Margin | -3851.09% |
| FCF Margin | -3068.02% |
| Gross Margin (5Y Average) | 75.41% |
Dividends and Yields
CGON does not pay a dividend. Its free cash flow yield is -2.70%.
| FCF Yield | -2.70% |
|---|---|
| Buyback Yield | -6.98% |
| Shareholder Yield | -6.98% |
Peer Position
Against 5 similar companies, CGON has the 2nd highest ROIC.
ROICPeer median -65.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +49.45%
| ROIC | -21.06% vs -65.96% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +169.85% vs +49.45% median |
Analyst Forecast
Consensus estimates put revenue growth at 384.46% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +384.46% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CGON
What is CGON's market cap?
CG Oncology, Inc. Common stock has a market cap of $7.57B. Its enterprise value, which adds debt and subtracts cash, is $7.55B.
How many shares of CGON are outstanding?
CG Oncology, Inc. Common stock has 88.87M shares outstanding. The count is up 15.82% from a year earlier.
Does CGON pay a dividend?
No. CG Oncology, Inc. Common stock does not pay a dividend.
How much debt does CGON have?
CG Oncology, Inc. Common stock has $3.00M of total debt and $28.25M of cash and equivalents, a net cash position of $25.25M.
CGON pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors